Neovascular Age-Related Macular Degeneration (nAMD) Clinical Trials

8 recruitingLast updated: May 21, 2026

There are 8 actively recruiting neovascular age-related macular degeneration (namd) clinical trials across 16 countries. Studies span Phase 3, Phase 2, Early Phase 1, Phase 1. Top locations include Dallas, Texas, United States, Austin, Texas, United States, Erie, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Neovascular Age-Related Macular Degeneration (nAMD) Trials at a Glance

8 actively recruiting trials for neovascular age-related macular degeneration (namd) are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 3 with 4 trials, with the heaviest enrollment activity in Dallas, Austin, and Erie. Lead sponsors running neovascular age-related macular degeneration (namd) studies include Adverum Biotechnologies, Inc., Alcon Research, and 4D Molecular Therapeutics.

Browse neovascular age-related macular degeneration (namd) trials by phase

About Neovascular Age-Related Macular Degeneration (nAMD) Clinical Trials

Looking for clinical trials for Neovascular Age-Related Macular Degeneration (nAMD)? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neovascular Age-Related Macular Degeneration (nAMD) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neovascular Age-Related Macular Degeneration (nAMD) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled36 locationsNCT07482176
Recruiting
Phase 3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics480 enrolled94 locationsNCT07064759
Recruiting

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
Bayer50,000 enrolled1 locationNCT07308639
Recruiting
Phase 3

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Innostellar Biotherapeutics Co.,Ltd332 enrolled31 locationsNCT07317934
Recruiting
Phase 1Phase 2

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-Related Macular Degeneration (nAMD)
Alcon Research140 enrolled42 locationsNCT05769153
Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled79 locationsNCT06856577
Recruiting
Early Phase 1

CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

Neovascular Age-Related Macular Degeneration (nAMD)
HuidaGene Therapeutics Co., Ltd.12 enrolled2 locationsNCT06031727
Recruiting
Phase 2

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)
EyebioKorea, Inc.50 enrolled5 locationsNCT06487039